Team

The scientific team at RetinalGeniX is led by Lloyd Paul Aiello, M.D., Ph.D., Head of Joslin Diabetes Centers’ Section on Eye Research, Director of Joslin’s Beetham Eye Institute, and Associate Professor of Ophthalmology at Harvard Medical School. Director of Clinical Affairs . Dr. Aiello is the author of more than 60 original papers and over 100 publications and the recipient of 20 national and international awards. He has served as Chair for two Medical Science Review Committees of the Juvenile Diabetes Research Foundation, the American Diabetes Association Lions SightFirst Diabetic Retinopathy Research Program and the National Institutes of Health sponsored Diabetic Retinopathy Clinical Research Network.

Dr. Ahmed Mohiuddin, Senior Advisor

  • Director, New England Heart Center Foundation, Medical Center Of Boston International
  • Chairman & CEO Medical Center Of Boston International, New England Heart Center PC
  • Member Of The Leadership Council Harvard School Of Public Health
  • Member Of The Nutritional Round Table, Harvard school Of Public Health
  • Diplomat American Board Of Internal Medicine
  • Diplomat American Board, Cardio-Vascular Diseases
  • Fellow of the American College of Cardiology
 

Lloyd Paul Aiello, M.D., Ph.D.

  • Head, Eye Research, and Director, Beetham Eye Institute, Joslin Diabetes Center.
  • Associate Professor, Ophthalmology, Harvard Medical School.
  • Author of more than 60 papers and over 100 publications and the recipient of 20 national and international awards.
  • Chair for two Medical Science Review Committees of Juvenile Diabetes Research Foundation: American Diabetes Association Lions SightFirst Diabetic Retinopathy Research Program, and National Institutes of Health sponsored Diabetic Retinopathy Clinical Research Network.
  • Recognized internationally for leadership in diabetic retinopathy; Chair of 3 multicenter, multinational, phase 3 clinical trials, results of which will determine whether an oral inhibitor can delay or prevent development of sight-threatening conditions of proliferative diabetic retinopathy. 

Frank L. Wang, Ph.D.

  • Primary Investigator, Federal DoD/IHS/CDMP programs at Beetham Eye Institute of Joslin Diabetes Center; scientist at Joslin, Harvard Medical School
  • As an investigator, he is responsible for managing various federal diabetes research and development programs of Joslin Vision Network (JVN), sponsored by Department of Defense, Indian Health Services, Joslin, and Harvard Medical School at more than 100 federal clinical sites.
  • Since joining Joslin in 2005, Dr. Wang has managed several major R&D projects for Joslin Vision Network, including an automated treatment plan for diabetic retinopathy (DR); and medical imaging applications for acquiring, storing, and displaying high-quality ophthalmic images. Specializes in FDA rules and regulations for non-invasive medical devices. 

Jennifer K. Sun, MD

  • Investigator, Section on Vascular Biology, Joslin Diabetes Center; ophthalmologist, Beetham Eye Institute at Joslin; Assistant Professor, Harvard Medical School.
  • In collaboration with George King, M.D., Head, Section on Vascular Biology and Director of Research, Dr. Sun is analyzing data from the 50-Year Medalist cohort on patients who have lived with diabetes for 50 years or more. Dr. Sun is closely examining a range of data from the patients in this cohort in the hope of identifying genetic or biochemical markers that correlate with good long-term ophthalmologic outcomes and could be therapeutically targeted in patients with diabetes who have early-stage vision complications.